PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16263322-1	2005	We investigated the clinical efficacy and tolerability of 45 mg/day mosapride, a selective 5-hydroxytryptamine type 4 (5-HT4) agonist, in an open-label study involving five patients with Parkinson"s disease (PD) who had response fluctuations (RFs).	mosapride	68-77	5-hydroxytryptamine receptor 4	Homo sapiens	119-124	
26303048-2	2015	Mosapride citrate is a 5-hydroxytryptamine receptor 4 (5-HT4) agonist, which is shown to improve upper abdominal symptoms.	mosapride	0-17	5-hydroxytryptamine receptor 4	Homo sapiens	23-53